Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3444-3451

  Zheng, Xi ^a   Chang, Richard L ^a   Cui, Xiao Xing ^a   Avila, Gina E ^a   Hebbar, Vidya ^a   Garzotto, Mark ^c   Shih, Weichung Joe ^d,e   Lin, Yong ^d,e   Lu, Shou En ^d,e   Rabson, Arnold B ^b,e   Kong, Ah Ng Tony ^a   Conney, Allan H ^a,e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INJECTIONS, INTRAPERITONEAL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, NUDE; MICE, SCID; PACLITAXEL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRADECANOYLPHORBOL ACETATE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745208935     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2823     Document Type: Article

References (35)

1. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci U S A 1998;95:5357-61.
2. Han ZT, Tong YK, He LM, et al. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci U S A 1998;95:5362-5.
3. Strair RK, Schaar D, Goodell L, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002;8:2512-8.
4. Schaar D, Goodell L, Aisner J, et al. A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 2005;18:1-7.
5. Zheng X, Chang RL, Cui XX, et al. Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans-retinoic acid, 1α,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 2001;12:419-27.
6. Altuwaijri S, Lin HK, Chuang KH, et al. Interruption of nuclear factor κB signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003;63:7106-12.
7. Garzotto M, White-Jones M, Jiang Y, et al. 12-O-tetradecanoylphorbol-13- acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 1998;58:2260-4.
8. Gonzalez-Guerrico AM, Kazanietz MG. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase Cδ. J Biol Chem 2005;280:38982-91.
9. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistent membrane translocation of protein kinase Cα during 12-O- tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differentiation 1996;7:419-28.
10. Fujii T, Garcia-Bermejo ML, Bernabo JL, et al. Involvement of protein kinase Cδ (PKCδ) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCδ. J Biol Chem 2000;275:7574-82.
11. Konno S, Hsieh TC, Wu JM, Chen Y, Chiao JW, Mallouh C. Growth control of human prostatic cancer cells by the phorbol ester TPA: possible involvement of protein kinases. Anticancer Res 1996;16:1843-9.
12. Garzotto M, Haimovitz-Friedman A, Liao WC, et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999;59:5194-201.
13. Zheng X, Chang RL, Cui XX, et al. Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 2004;64:1811-20.
14. Bokemeyer C, Hartmann JT, Kuczyk MA, et al. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol 1998;16:155-62.
15. Lapidus RG, Dang W, Rosen DM, et al. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation. Prostate 2004;58:291-8.
16. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72:2457-60.
17. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-63.
18. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44-53.
19. + human bone marrow progenitor cells. Mol Pharmacol 1996;50:610-5.
20. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994;50:834-41.
21. Satterthwaite FW. An approximate distribution of estimates of variance components. Biometrics Bull 1946;2:110-4.
22. Lindsey JK. Models for repeated measurements. Oxford: Claredon Press; 1993.
23. Cui XX, Chang RL, Zheng X, Wood ward D, Strair R, Conney AH. A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 2002;13:169-74.
24. de Jonge ME, van den Bongard HJ, Huitema AD, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44.
25. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002;21:1017-27.
26. Hershberger PA, Yu WD, Modzelewski RA, et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-51.
27. de Souza PL, Castillo M, Myers CE. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br J Cancer 1997;75:1593-600.
28. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000;289:1159-64.
29. Ikezoe T, Yang Y, Taguchi H, Koeffler HP. JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-O-tetradecanoylphorbol-13-acetate (TPA). Br J Cancer 2004;90:2017-24.
30. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
31. Derry WB, Wilson L, Jordan MA. Low potency of Taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism. Cancer Res 1998;58:1177-84.
32. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
33. Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-36.
34. Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60.
35. Das KC, Guo XL, White CW. Protein kinase Cδ-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem 1998;273:34639-45.